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MicroRNA (miR) 155 has been implicated in the regulation of innate and adaptive
immunity as well as autoimmune processes. Importantly, it has been shown to regulate
several antiviral responses, but its contribution to the immune response against
cytopathic viruses such as vesicular stomatitis virus (VSV) infections is not known. Using
transgenic/recombinant VSV expressing ovalbumin, we show that miR-155 is crucially
involved in regulating the T helper cell response against this virus. Our experiments
indicate that miR-155 in CD4+ T cells controls their activation, proliferation, and cytokine
production in vitro and in vivo upon immunization with OVA as well as during VSV viral
infection. Using intravital multiphoton microscopy we analyzed the interaction of antigen
presenting cells (APCs) and T cells after OVA immunization and found impaired complex
formation when using miR-155 deficient CD4+ T cells compared to wildtype CD4+ T
cells ex vivo. In contrast, miR-155 was dispensable for the maturation of myeloid APCs
and for their T cell stimulatory capacity. Our data provide the first evidence that miR-155
is required for efficient CD4+ T cell activation during anti-viral defense by allowing robust
APC-T cell interaction required for activation and cytokine production of virus specific
T cells.
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INTRODUCTION
T cell activation has to be tightly controlled to allow an efficient immune response against infectious
diseases but also to prevent autoimmunity. MicroRNAs (miRs) have been implicated in both
processes and are therefore interesting targets to study immune regulation. In particular, miR-155
has been shown to regulate many aspects of the immune system (1–3). It is involved in the
regulation of macrophage and dendritic cell biology, including cytokine production by targeting
PU-1 and SHIP-1 (4–6). In B cells, this microRNA has been demonstrated to control germinal
center formation and the generation of class switched antibodies (7–9). CD4+ T cells of miR-155
deficient mice were shown to have a bias toward a Th2 phenotype, while overexpression of miR-155
promotes a Th1 phenotype (7, 10). The increased Th2 differentiation potential of miR-155 deficient
CD4+ T cells was attributed to an up-regulation of c-Maf, a potent transcription factor of the IL-4
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promoter and a miR-155 target (7). MiR-155 also targets IFNγRα
in CD4+ cells cultured under Th1 conditions, which is one
of the multiple known targets responsible for the inhibition
of Th1 differentiation of miR-155−/− CD4+ T helper cells
(10). MiR-155 deficient mice have an impaired capacity for
polarization of T helper cells into Th17 and follicular T helper
cells (11, 12).
We and others have previously shown, that miR-155 deficient
mice are protected from collagen induced arthritis due to reduced
generation of autoreactive T and B cells (13, 14). Also, in
experimental autoimmune encephalitis (EAE), protection from
disease in miR-155 deficient mice was mediated primarily by
reduced generation of pathogenic T cells. In arthritis, miR-155
also plays an important role in myeloid cells, since it controls
the expression of pro-inflammatory cytokines and chemokines
in monocytes and macrophages (14). In addition, miR-155 has
been implicated in dendritic cell (DC) function, as it is highly
upregulated during their maturation. However, its functional role
in DCs has remained controversial (5, 6, 15–17).
During host response to viral infections, miR-155 has been
demonstrated to be critically involved in CD8+ cytotoxic T
cell activation by controlling interferon signaling and SOCS1
expression (18). This mechanism has been shown to be very
important in host response to viral infections, especially in
lymphocytic choriomeningitis virus (LCMV) and influenza
infection (18, 19). In macrophages infected with vesicular
stomatitis virus (VSV), miR-155 was shown to be important to
control viral replication via targeting SOCS1 in vitro (20).
Cytopathic viruses such as VSV and vaccinia do not
essentially require CD8+ T cells for host defense, but crucially
rely on CD4+ T helper cells and neutralizing antibody
producing B cells (21–25). However, the role of miR-155 in
this process is not known. We have therefore analyzed the
role of miR-155 in T helper cell responses toward vesicular
stomatitis virus (VSV) using recombinant viruses expressing
ovalbumin, which allowed us to track antiviral T cell responses
using ovalbumin-specific T cell receptor (TCR) transgenic
OTII T cells.
MATERIALS AND METHODS
Animals
All mice used were on a C57BL/6 background. MiR-155−/−,
wild-type (WT), ovalbumin-specific Tcrα/Tcrβ transgenic (OTII)
mice were obtained from Jackson Laboratories and bred in
house (Biomedical Research Facility, Medical University of
Vienna). To obtain miR-155−/− OTII mice and miR-155+/+
OTII littermates, WT OTII mice were crossed with miR-155−/−
mice. CD45.1 mice were kindly provided by the group of
Dr. Silvia Knapp (Medical University of Vienna), transgenic
mice carrying the IghelMD4 transgene that recognizes hen egg
lysozyme (HEL) and CD11c-YFP mice were bred in the Center
Research, University of Glasgow. All animals, except the CD45.1
mice, express the Ptprcb (CD45.2) allele. All animal studies were
approved by the animal ethics committee from the Medical
University Vienna and the University of Glasgow and comply
with institutional guidelines.
Preparation of Primary Cells, Mixed
Lymphocyte Reaction, Proliferation Assays
Dendritic cells (DCs) were generated from WT or miR-155−/−
mice similarly as described before (Lutz et al). Briefly, bone
marrow cells flushed from femur and tibia of mice were
cultured in complete RPMI-1640 medium containing 10%
fetal bovine serum, 2mM L-glutamine, penincilin (100 U/mL),
streptomycin (100 ug/mL) (all from Gibco) supplemented
with 20 ng/mL mGM-CSF (R&D). After 7–9 days of culture,
BMDCs were matured for 24 h in complete RPMI supplemented
with 10µg/mL E.coli LPS (Sigma). For mixed lymphocyte
reaction (MLR), CD4+ cells were isolated from splenocytes of
WT or miR-155−/− OTII mice by magnetic cell separation
(MACS) using the CD4+ isolation kit according to manufacture
recommendations (Miltenyi Biotec, Germany), and co-cultured
with DCs in the presence of Ovalbumin (OVA) or ovalbumin
peptide 323–339 (pOVA) (both AnaSpec, CA, USA) in the
indicated concentrations for 96 h. Alternatively, MACS isolated
CD4+ splenocytes were cultured in complete RPMI in 96 well
plates (100,000 cells/well) coated with anti-CD28 (3µg/mL) and
anti-CD3 (1µg/mL; both from BioXCell, NH, USA) for 96 h.
Cell proliferation was quantified by H3-Thymidine (1 µCi/well)
incorporation during the last 18 h of culture and presented as
mean value of six technical replicates per condition, both in
the MLR and in the plate bound antibody-induced proliferation
assays. Quantification was done on a TopCount R©NXTTM
microplate scintillation counter (Packard, CT, USA).
Adoptive Cell Transfer
Magnetically separated WT or miR-155−/− OTII CD4+ T cells,
were labeled with 10µg/mL CFSE (life technologies, CA, USA)
in PBS for 20min at 37◦C as recommended by the manufacturer
(10 × 106 cells/ml). After labeling, 2–5 × 106 cells/mouse
were injected intravenously into either WT, miR-155−/− or
CD45.1 mice. For multiphoton imaging, 2–5 × 106 cells/mouse
were labeled with 5µM Cell Tracker Red (CMTPX, Invitrogen,
Paisley, Scotland, UK) in CO2-independent media (Invitrogen,
Paisley, Scotland, UK) for 40min at 37◦C, and injected i.v. into
CD11c-YFP mice. For immunization experiments with HEL-
OVA, OTII T cells, and MD4 B cells were prepared and injected
as described before (26).
RVSV-OVA Infection and Protein
Immunization
Recombinant VSV-OVA virus (rVSV-OVA) was kindly provided
by Mike Bevan and was initially designed by Dr. Leo LeFrancois
(27). For the rVSV-OVA infection each WT or miR-155−/−
mice received intravenously 2× 105 plaque forming units (PFU)
of rVSV-OVA diluted in BSS. CD45.1 mice were infected with
the same amount of virus 1 day after adoptive T cell transfer.
Eight days after infection, blood and spleen were collected from
each animal. Protein immunizations after adoptive T cell transfer
were done either i.v. with a solution of LPS and OVA (75 and
30 µg/mouse, respectively) or s.c. in the footpad with 130 µg
conjugated HEL-OVA in complete Freund’s adjuvant (Sigma),
prepared as previously described (28). In mice immunized with
Frontiers in Immunology | www.frontiersin.org 2 June 2019 | Volume 10 | Article 1367
Goncalves-Alves et al. The Role of MiR-155 in VSV Infection
LPS and OVA spleens were collected 96 h after immunization; in
mice immunized with HEL-OVA the axial and brachial LNs were
collected 6 days after immunization.
In vitro Re-stimulation Assay
Splenocytes (1 × 105 per well) were cultured in complete
RPMI in the presence of 5µg/mL of pOVA (ovalbumin
peptide 323–339, AnaSpec) in a 96 well plate for 96 h, 50
µL of cell culture supernatant were collected for cytokine
quantification. Cell proliferation was quantified by H3-
Thymidine (1 µCi/well) incorporation in the last 18 h of culture,
six technical replicates were used per mouse. Quantification
was on a TopCount R©NXTTM microplate scintillation counter
(Packard, CT, USA).
Neutralizing Antibody Assay
VSV-neutralizing antibody titers were quantified as previously
described (29). Concisely, mouse serum was diluted 40-fold in
MEMcontaining 5% FCS and heat inactivated for 30min at 56◦C.
Serial 2-fold dilutions were incubated for 90min at 37◦C in an
equal volume of rVSV-OVA solution containing 1,500 PFU/mL.
Serum-virus solution was transferred onto Vero cell (ATCC, VI,
USA) monolayers and incubated for 90min at 37◦C, after which
the cells were overlaid withMEM containing 1%methylcellulose.
Cells were fixed and stained with 0.5% crystal violet solution after
24 h of incubation at 37◦C, 5%CO2. Antibody titer was calculated
as the highest dilution of serum that reduced the number of
plaques by at least 50%.
Antibodies ELISA and FlowCytomix
Analysis
Anti-OVA and Anti-HEL antibodies were detected as previously
described (28). Soluble forms of IL-2, TNFα, IFN-γ, and IL-
4 were detected using the FlowCytomix kit according to the
manufacturer’s recommendations (Bender MedSystems, GmbH,
Vienna, Austria).
Real Time PCR
RNA isolation of sorted dendritic cells and stimulated T cells was
done using the RNeasy Mini kit (Qiagen), for cDNA synthesis
the Omniscrip kit (Qiagen) was used. Real-time PCR was done
in a Light cycler 480 (Roche) using SYBR R© green master mix
and the following primer pairs: IL-12p40 fwd: 5′-GAC ACG CCT
GAAGAAGATGAC-3′, rev.: 5′-TAGTCCCTTTGGTCCAGT
GTG-3′; IL-12p35 fwd: 5′-CCC TTG CCC TCC TAA ACC AC-
3′, rev: 5′-AAG GAA CCC TTA GAG TGC TTA CT-3′; IL-23
fwd: 5′-ATG CTG GAT TGC AGA GCA GTA-3′ rev: 5′-ACG
GGG CAC ATT ATT TTT AGT CT-3′; IL-6 fwd: 5′- GCC CAA
ACA CCA AGT CAA GT-3′ rev: 5′-TAT AGG AAA CAG CGG
GTT GG-3′; TNFα fwd: 5′-AGC CCC CAG TCT GTA TCC TT-
3′ rev: 5′-CTC CCT TTG CAG AAC TCA GG-3′; GAPDH fwd:
5
′
-TGG CAT TGT GGA AGG GCT CAT GAC-3′ rev: 5′-ATG
CCA GTG AGC TTG CCG TTC AGC-3′. GAPDH was used as
house-keeping gene for normalization.
Flow Cytometry
Antibodies used for the different staining panels were the
following: CD4 (rat anti-mouse, eBioscience); CD25, TCR Vα2,
CD8a, B220, CD3, CD4 (rat anti-mouse, BioLegend); CD62L,
CD44, CD86, I-A/I-E MHC II, CD40, GR-1, CD11b (rat anti-
mouse, BD Biosciences); CD11c, CD86 (hamster anti-mouse, BD
Biosciences); CD69 (hamster anti-mouse, BioLegend); CD45.2
(mouse anti-mouse, BD Biosciences). Spleens or lymph nodes
(LN) were harvested and passed through a nylonmash to obtain a
single cell suspensions. Cells were then stained with the indicated
antibodies in FACS buffer (PBS+1% FCS) for 30min at 4◦C.
After staining cells were washed and analyzed by flow cytometry
in either a FACS-Canto, LSRII or FACS-Verse (BD Biosciences).
Data was analyzed using FlowJo.
Multiphoton Microscopy
Multiphoton imaging was done using a Zeiss LSM7 MP
System equipped with a 20x/1.0NA water-immersion objective
lens (Zeiss UK, Cambridge, UK) and a tunable Titanium:
sapphire solid-state two-photon excitation source (Chamelon
Ultra II; Coherent Laser Group, Glasgow, UK) and optical
parametric oscillator (OPO; Coherent Laser Group). Popliteal
LNs were excised 24 h after immunization, transferred into CO2-
independent media at room temperature and bound onto a
plastic coverslip with veterinary glue (Vetbond, 3M, St. Paul,
MN). Grease was used to attach the coverslip to the bottom of the
imaging chamber, which was supplied with warmed (36.5◦C) and
gassed (95% O2 and 5% CO2) RPMI 1640 before and during the
imaging. A laser output of 820 nm and OPO signal at 1,060 nm
provided excitation of YFP CD11c- and DS-Red OTII T cells.
Acquisition of the videos was done for 20–30min with X-Y pixel
resolution of 512× 512 inches in 2µm. Cellular 3D tracking was
done using Volocity 6.1.1 (Perkin Elmer, Cambridge, UK). Mean
velocity, displacement and meandering index was calculated for
each object. Intersection of DsREd and YFP objects was used
to determine interaction between T cells and DCs, respectively
(28, 30).
Statistical Analysis
Results are shown as mean ± SEM unless otherwise stated,
statistical significance was determined using two-tailed Mann-
Whitney-test, whenmultiple comparisons were made Bonferroni
correction was used. A p-value< 0.05 was considered significant.
RESULTS
Reduced Host Response to VSV Infection
in miR-155 Deficient Mice
To test whether miR-155 is involved in the generation of anti-
viral responses to cytopathic viral infection, wild-type (WT)
and miR-155 deficient mice (miR-155−/−) were infected with
VSV. In serum of infected animals on day 8, miR-155 deficient
mice showed a significant decrease in neutralizing antibodies
against VSV (Figure 1A). In addition, we detected increased
numbers of naïve (CD4+CD62L+CD44−) and reduced numbers
of memory (CD4+CD62L−CD44+) T cells in miR-155 deficient
mice compared to WTmice (Figures 1B,C), demonstrating both
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impaired antiviral antibody production as well as decreased
T helper cell activation during VSV infection in miR-155
deficient mice.
DC Maturation Is Not Affected by Absence
of miR-155
We next asked, whether reduced activation of T helper cells
could be due to impaired function of antigen presenting cells
(APCs). So far, the role of miR-155 in the activation and
function of APCs, especially DCs, has been controversial (5,
6). Therefore, we analyzed how miR-155 affects dendritic cell
function both in vitro and in vivo in our setting. First, we
generated bone marrow-derived dendritic cells (BMDCs) from
WT and miR-155−/− mice and evaluated the expression of
co-stimulatory molecules. Upregulation of CD80 (p = 0.1268),
CD86 (p = 0.444), CD40 (p = 0.444) as well as MHC II
(p = 0.444) were not significantly different 24 h post LPS
stimulation (Figure 2A).
We next tested maturation of DCs in vivo by analyzing
up-regulation of maturation markers and the expression
of pro-inflammatory cytokines of CD11c+ DCs after LPS
administration intraperitoneally in WT and miR-155−/− mice.
Up-regulation of CD80 (p = 1), CD86 (p = 0.8344), CD40
(p = 1), and MHC II (p = 1) was similar and independent of
miR-155 presence (Figure 2B). To evaluate mRNA expression
levels of pro-inflammatory cytokines, we sorted CD11c+ cells
and quantified RNA expression levels of IL-12, IL-23p19, IL-6,
and TNFα by qPCR.We saw no differences betweenmiR-155−/−
and WT CD11c+ DCs (Figure 2C). In addition, we quantified
the amount of pro-inflammatory cytokines present in the serum
after LPS administration and saw that miR-155 deficient mice
produced a similar amount of IL-6, TNFα, and IL-12 as compared
to WT mice (Figure S1).
Lack of miR-155 Does Not Influence T Cell
Stimulatory Capacity of DCs
Next, we were interested in determining whether the absence
of miR-155 in dendritic cells affected their capacity to activate
CD4+ T cells. To this end, we loadedWTormiR-155−/− BMDCs
with ovalbumin (OVA) and co-cultured them with OTII T cells
expressing a transgenic T cell receptor (TCR) recognizing the
OVA peptide 323–339. We observed that the proliferation of
OTII T cells induced by miR-155 deficient or sufficient BMDCs
was similar, regardless of the concentration of OVA (Figure 3A).
To analyze the impact of miR-155 on the capacity of APCs
to stimulate T cells in vivo, we transferred CFSE labeled OTII
T cells into WT and miR-155−/− mice and quantified their
proliferation after immunization with OVA and LPS by CFSE
dilution. Proliferation (i.e., CFSE dilution) of WT OTII T cells
was even increased when these cells were transferred to miR-
155 deficient mice compared to WT mice (Figure 3B). Taken
together, our data demonstrates that the absence of miR-155 does
not affect phenotypic maturation and MHC class II presentation
capacities of DCs neither in vitro nor in vivo.
Lack of miR-155 Affects the Proliferative
Capacity of CD4+ T Cells
To investigate the role of miR-155 in T helper cell activation
and proliferation, we crossed miR-155−/− mice with OTII mice
to generate miR-155 sufficient (WT OTII) and deficient (miR-
155−/− OTII) OTII mice. We then co-cultured WT OTII and
miR-155 OTII CD4+ T cells with WT BMDCs in the presence of
different OVA concentrations and quantified their proliferation.
As shown in Figure 3C, miR-155−/− OTII T cells proliferated
significantly less than their WT counterparts after stimulation.
When we measured levels of different cytokines present in the
supernatants of these co-cultures, we also found a significantly
reduced production of IL-2 and IFN-γ (Figure S2). However,
when we used plate bound anti-CD3 or anti-CD3/CD28 to
stimulate either MACS isolated or FACS-sorted CD4+ T cells,
there were no significant differences in the proliferative response
(Figure 3D) or in cytokine production (Figure S3) between WT
and miR-155 deficient cells.
We then tested whether miR-155 expression affected CD4+ T
cell proliferation in vivo. For this, we transferred CFSE labeled
WT OTII or miR-155−/− OTII T cells into WT mice and
immunized these with LPS alone or the combination of LPS
and OVA. In order to easily identify the transferred OTII T
cells (derived from CD45.2 mice), we used CD45.1 mice as
recipients. In line with our in vitro data, there was a lower
proliferative response of the transferred miR-155−/− OTII T
cells in comparison to WT OTII T cells in vivo (Figure 3E).
We also measured the relative abundance of transferred OTII
T cells over time. Mice received WT or miR-155−/− OTII T
cells with or without immunization with LPS-OVA. In non-
immunized mice, the relative numbers of transferred OTII T
cells remained constant at all time points analyzed. In mice
immunized with LPS+OVA that had received WT OTII T cells,
there was a significant expansion of the transferred OTII T
cells at day 5 after immunization. In contrast we did not detect
increased numbers of transferred miR-155−/− OTII T cells after
immunization at all time points analyzed (Figure 3F). These data
suggest that miR-155 is necessary for proliferation and expansion
after immunization of CD4+ T cells after immunization in vivo.
CD4+ T Cell Interaction With DCs Is
Controlled by miR-155
As our previous experiments demonstrated a reduced activation
of miR-155 deficient CD4+ T cells only upon activation by
APCs, which could be overcome by antibody-mediated direct
stimulation of CD3 and CD28, we wanted to investigate the
mechanism leading to this striking difference in more detail.
It has been shown that the quality of DC and CD4+ T cell
interaction is crucial for efficient T helper cell response (30, 31).
Using multiphoton microscopy, we investigated whether lack of
miR-155 in T cells could affect DC/T cell interaction. To this
end, miR-155 sufficient or deficient OTII T cells were labeled
with the fluorescent dye CMTPX and then transferred into WT
CD11c-YFP mice that were immunized with OVA in CFA on the
same day of cell transfer. After 24 h, popliteal lymph nodes (LN)
were collected and imaged. Analysis of three different areas in
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FIGURE 1 | Reduced host response to VSV infection in miR-155 deficient mice. (A) MiR-155−/− and WT mice were infected intravenously with
Ovalbumin-expressing rVSV (2 × 105 PFU/mL). After 8 days of infection, animals were sacrificed and serum and spleens were collected. Quantification of anti-VSV
neutralizing antibodies present in mouse serum was done via VSV-specific plaque assay, as explained in material and methods Frequencies of naïve Th cells
(CD62L+CD4+) (B) and memory Th cells (CD44+CD4+) (C) present in the spleen were quantified by flow cytometry. Data is presented as mean ± SEM, and
representative of two independent experiments (n = 6–8 mice). Statistical significance was calculated using two-tailed Mann-Whitney test. *p ≤ 0.05, ***p < 0.001.
FIGURE 2 | MiR-155 deficiency does not modify activation and function of DCs. (A) WT and miR-155−/− BMDCs cultured for 24 h in the presence or absence of
LPS (10µg/mL) were analyzed for the expression of CD80, CD86, CD40, and MHC II (MHC II) by flow cytometry. Bars show mean fluorescence intensity (MFI) ± SEM
of CD11c+Gr-1− gated cells (n = 5 per condition, pooled from two independent experiments). (B) MFI ± SEM of the expression of CD80, CD86, CD40, MHC II of
splenic CD11c+Gr-1− cells of WT and miR-155−/− mice 6 h after intraperitoneal injection of LPS (75 µg/mouse) or PBS (n = 5 per condition). (C) CD11c+Gr-1−
cells were FACS sorted from spleens of mice treated with LPS for 6 h and mRNA expressions levels of the pro-inflammatory cytokines IL-12, IL-23, IL-6, and TNFα was
quantified by qPCR (n = 5). Data is presented as mean ± SEM. Statistical significance was calculated using two-tailed Mann-Whitney test with Bonferroni correction.
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FIGURE 3 | Absence of miR-155 in CD4+ T cells leads to reduced clonal expansion. (A) WT or miR-155−/− BMDCs were co-cultured with WT OTII T cells in a 1:5
ratio in the presence of the indicated concentrations of OVA. Proliferation was quantified by H3-Thymidine incorporation. Results show mean values ± SEM of 6
technical replicates using two mice per genotype. The plot is representative of 3 independent experiments. (B) OTII T helper cells were stained with CFSE and
transferred i.v. into WT and miR-155−/− mice. One day later mice were immunized i.v. with LPS (75 µg/mouse) and OVA (30 µg/mouse). Cell proliferation was
quantified 3 days after immunization using flow cytometry by measuring CFSE mean fluorescence intensity of Vα2+ cells, gated on CD4+ cells in the spleen (n = 5 for
each genotype). (C) WT or miR-155−/− OTII T cells were co-cultured with WT BMDCs in a 1:5 ratio in the presence of the indicated concentrations of OVA.
Proliferation was quantified by H3-Thymidine incorporation. Results show mean values ± SEM of 6 technical replicates and two mice per genotype. The plot is
representative of 3 independent experiments. (D) CD4+ cells were MACS isolated from spleen of WT or miR-155−/− mice and seeded in 96 well plates pre-coated
with anti-CD3 (1µg/mL) and anti-CD28 (3µg/mL). Proliferation was quantified by H3-Thymidine incorporation. Results show mean values ± SEM of 6 technical
replicates and two mice per genotype. The plot is representative of 3 independent experiments. (E) WT or miR-155−/− OTII T cells were stained with CFSE and
transferred i.v. into WT. Mice were immunized i.v. with LPS (75 µg/mouse) with OVA (30 µg/mouse). Cell expansion was quantified 3 days after immunization using
flow cytometry by measuring CFSE mean fluorescence intensity of Vα2+ cells, gated on CD4 + cells (n = 8 for each genotype). (F) WT or miR-155−/− OTII T helper
cells were transferred i.v. into CD45.1 mice (immunization was done as referred above). Frequency of CD45.2+Vα2+ cells of gated CD4 + cells, present 3, 5, 7, or 9
days after immunization was done using flow cytometry (n = 3 per condition and genotype). Data is presented as mean ± SEM, statistical significance was calculated
using two-tailed Mann-Whitney test with Bonferroni correction for all panels except (F) where Two-way ANOVA was used. Significance shown reflect comparison of
WT vs. miR-155−/−. *p < 0.05, ***p < 0.001.
each LN revealed that miR-155−/− OTII T cells moved further
(p = 0.0001), with a higher velocity (p = 0.0001) and with a
higher meandering index (p = 0.0018) compared to WT OTII
(Figures 4A–C; Videos S1, S2). Additionally, we analyzed the
formation of clusters in the LN and their interaction times.
There were numerically more stable clusters of WT OTII T cells
with CD11c+ cells than of miR-155−/− OTII T cells (Figure 4D,
p= 0.6290). These data suggest, that miR-155 deficiency in CD4+
T cells is crucial for correct DC/T cell interaction.
miR-155 Deficiency in T Helper Cells Leads
to Reduced B Cell Expansion and
Antibody Production
Having established that miR-155 in CD4+ T cells is important
for APC-mediated proliferation and cytokine production in
vitro and in vivo, we asked, whether this is relevant during
viral infection. Using an ovalbumin encoding transgenic VSV
(VSV-Ova), we first analyzed, whether infusion of WT OTII
T cells could boost the generation of neutralizing antibodies.
However, administration of neither WT nor miR-155 deficient
OTII T cells changed the levels of neutralizing antibodies
(Figure S4). To test, whether miR-155 plays a role in the
B cell stimulatory capacity of T cells in a different setting,
we transferred miR-155 sufficient and deficient OTII T cells
and B cells of BCR transgenic mice, which express a BCR
recognizing HEL. This system allows evaluation of anti-HEL
B cell responses which depend on help from OTII T cells in
response to a HEL-OVA fusion protein (28). Immunization with
HEL-OVA+CFA led to an expansion of WT OTII T cells; in
contrast miR-155−/− OTII T cells expansion was significantly
lower (Figure 5A, p = 0.0316). When we analyzed the capacity
of OTII T cells to induce expansion of antigen specific B cells,
we found significantly reduced HEL BCR transgenic B cells
in mice that had received miR-155−/− OTII T cells compared
to WT OTII T cells (Figure 5B, p = 0.0316). The production
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FIGURE 4 | MiR-155 in CD4+ T cells is required for proper DC-T cell interactions. CD11c-YFP mice received 5 × 106 WT or miR-155 OTII T cells labeled with
CMTPX and were immediately immunized with OVA/CFA in the footpad. Popliteal LNs were collected 24 h after immunization, three random regions of each LN were
imaged and Volocity software was used for semi-automated tracking. Each point represents a single tracked object, either a single cell or the interaction (intersection
between the DC and T cell fluorescent signal). Mean velocity (A), displacement rate (B), meandering index (C), and interaction time between DCs and T cells (D) were
quantified using Volocity software programs. Data are presented as mean ± SEM, two-tailed Mann-Whiney test and representative of two animals per group of at
least two independent experiments. ***p ≤ 0.001, **p ≤ 0.01.
of anti-HEL IgMa production was also affected by the lack
of miR-155 on the T cells, since there were significantly less
anti-HEL IgMa antibodies in the serum of animals which
received miR-155 deficient OTII T cells (Figure 5C, 200 dilution
p = 0.0060, 400 dilution p = 0.0122, 800 dilution p = 0.2385,
1,600 dilution p = 1). This data clearly demonstrates an
important role for miR-155 in the activation of B cells by T
helper cells.
Absence of miR-155 Impacts CD4+ T Cell
Response to rVSV and Vaccinia Virus
Previous studies showed a role of miR-155 in the CD8+ T cell
response to viral infection (18, 19, 32). However, also CD4+ T
cells are important in anti-viral defense (23, 33) and therefore
we were interested whether miR-155 was involved in the CD4+
T cell mediated response to viral infection. To study this, we
adoptively transferred miR-155−/− andWTOTII T cells isolated
from CD45.2 mice into CD45.1 WT recipient mice and infected
these with rVSV-Ova. Eight days after infection, 12% of the
total CD4+ T cells in the spleen were CD45.2+, suggesting a
robust expansion of WT OTII T cells after viral infection. In
contrast, in mice that had received miR-155 deficient OTII T
cells before infection with rVSV-Ova, only 2% of the overall
CD4+ population were CD45.2+ on day 8 (Figure 6A). To
analyze the recall response of WT and miR-155 deficient OTII
T cells ex vivo, we harvested the spleens 8 days after rVSV-Ova
infection and re-stimulated splenocytes ex vivo with OVA 323-
339 peptide. This peptide is only recognized by OTII T cells when
presented on MHC class II molecules, excluding stimulation of
MHC I restricted CD8+ T cells. Quantification of proliferation
demonstrated that splenocytes from mice which received miR-
155 deficient OTII T cells proliferated significantly less than those
that had received WT OTII T cells (Figure 6B). In addition, we
analyzed cytokine production from re-stimulated splenocytes in
the supernatant. We found that supernatants from mice that had
received miR-155 deficient OTII T cells contained significantly
lower levels of IL-2 (Figure 6C) and IFN-γ (Figure 6D). These
data suggest, that miR-155 is necessary for the generation and
activation of virus specific CD4+ T cells in response to a
viral infection.
DISCUSSION
MicroRNAs have been demonstrated to control various aspects of
both innate and adaptive immune responses, both in infections
and autoimmunity (34–37). Among them, miR-155 has been
shown to be important for the generation of both humoral
and cellular immune responses both during infection and
autoimmunity (4, 5, 13, 14). MiR-155 has been shown to be
critically important during infection with bacteria, but also
during viral infection requiring the generation of antiviral
CD8+ T cells. In this study, we demonstrate that miR-155
is required for the efficient generation of CD4+ T cell and
humoral responses to the cytopathic virus VSV. We show
that lack of miR-155 severely impairs efficient interaction
of T cells with APCs, inhibiting subsequent activation and
cytokine production of virus specific T cells in a T cell
intrinsic fashion.
While the role of T helper cells in viral infection is not
completely understood, the ability of CD4+ T cell to produce
cytokines has been linked to protection from lethal infection
with VSV. In addition, T helper cell-derived IL-2 has been
demonstrated to be crucial for the generation of anti-viral
CD8+ T cells in VSV infection (23–25). In our experiments,
using transgenic ovalbumin expressing VSV, we demonstrate
that without miR-155, T helper cells fail to expand during viral
infection and are incapable of producing significant amounts
of IL-2 and IFN-γ. Our in vivo immunization experiments
with ovalbumin and additional in vitro experiments demonstrate
that this failure in activation is T cell intrinsic, as miR-
155 deficient APCs are fully capable of activating WT OTII
T cells in vitro. In line, while we did notice numerically
reduced expression of co-stimulatory molecules of BMDCs
derived from miR-155 deficient mice in vitro, we did not
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FIGURE 5 | MiR-155 deficiency in T cells affects T cell help to B cells. (A) WT mice received 5 × 106 HEL-specific B cells and 5 × 106 WT or miR-155 OTII T cells
and brachial LN were collected 6 days after immunization with HEL-OVA/CFA. Expansion of transferred OTII T cells was quantified by flow cytometry as frequency of
Vα2+ cells gated on CD4+ cells. (B) Expansion of HEL-specific B cells was also analyzed by quantifying IgMa+ cells, gates on B220+ cells. (C) Serum was collected
at experimental endpoint and assessed for the presence of anti-HEL IgMa by ELISA. Data are presented as mean ± SEM and representative of two different
experiments (n = 6). Statistical significance was calculated using two-tailed Mann-Whitney test with Bonferroni correction in (A,B), while Two-way ANOVA was used in
(C). *p ≤ 0.05, **p ≤ 0.01.
FIGURE 6 | MiR-155 deficiency diminishes T helper cell activation during viral infection. (A) CD45.1 mice received 3 × 106 WT or miR-155 or WT OTII T cells, mice
were infected i.v. with rVSV the following day. Spleens were collected 8 days after infection. Expansion of transferred cells was quantified as percentage of CD45.2+
from all CD4+ cells. (B) Splenocytes were cultured for 3 days in full RPMI with or without OVA peptide (323–339) and proliferation was quantified by H3-Thymidine
incorporation. Flow Cytomix was used to quantify levels of IL-2 (C) and IFN-γ (D) present in the supernatant of splenocyte re-stimulation cultures. Data is presented
as mean ± SEM and representative of two independent experiments (n = 6). Statistical significance was calculated using two-tailed Mann-Whitney test with
Bonferroni correction. *p ≤ 0.05; ***p ≤ 0.001.
detect differences of DC maturation upon TLR4 stimulation in
vivo in the absence of miR-155. In addition, proliferation of
WT OTII T cells transferred into miR-155 deficient hosts was
even enhanced compared to proliferation of WT OTII T cells
transferred into WT hosts, demonstrating that in our system
miR-155 deficiency in APCs does not inhibit their ability to
stimulate T cell proliferation. Of note, and in line with our
data, Rothchild et al. also noted increased capacities of miR-155
deficient hosts to activate CD4+ T cells during mycobacterial
infection (38).
We also detected decreased titers of neutralizing antibodies
against VSV inmiR-155 deficientmice.While the role of miR-155
in B cells has been analyzed extensively, and plays an important
role in immunoglobulin class switch (8, 9), recent reports have
also identified miR-155 as an important regulator of follicular T
helper cell development (12, 39). In our experiments, employing
a HEL-OVA fusion protein, we could demonstrate an important
role of miR-155 in T cells and in their capacity to induce antigen
specific B cell proliferation and antibody production. Our results
suggest that the reduced anti-viral titers might be a consequence
of insufficient T cell help.
Mechanistically, we could show that miR-155 deficient T cells
form complexes with antigen bearing APCs after immunization
in vivo that are of reduced stability compared to the complexes
formed betweenAPCs andWTT cells, suggesting impaired APC-
T cell communication in the absence of miR-155 in T cells. In
line with this assumption, there was no difference in the ability of
WT or miR-155 deficient T helper cell to proliferate in response
to anti-CD3 and/or anti-CD28 stimulation in vitro, a fact that
has been noted by others as well (12). However, in all in vitro
and in vivo assays that required APC-T cell interaction there
was reduced a proliferation of CD4+ T cells lacking miR-155
compared to their WT counterparts. The most dramatic effects
were observed in our viral infectionmodels, were we could hardly
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detect any activation/proliferation in the ovalbumin specific (i.e.,
virus specific) miR-155 deficient T cells. It will be interesting
to determine the factors responsible for this effect. Of note,
miR-155 has been shown to control leukocyte adhesion to brain
endothelium (40), rendering adhesion molecules regulated by
miR-155 possible mediators of the observed impaired APC-T
cell communication.
Taken together, these data suggest that during viral infection,
proper APC-T cell interactions are crucial for the generation
of virus specific CD4+ T cell responses and that altering
this communication has dramatic consequences. It would be
interesting to investigate, whether APC-T cell communication is
also perturbed in CD8+ T cell activation.
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Figure S1 | WT and miR-155 mice were injected with LPS i.p.. After 6 hours,
serum was collected and the presence of IL-6 (A), TNFα (B) and IL-12p40 (C) was
quantified using Cytoplex analysis (n = 4). Data is presented as mean ± SEM.
Figure S2 | WT or miR-155−/− OTII T cells were co-cultured with WT BMDCs.
Supernatants were analyzed for the presence of (A) IL-2 and (B) IFN-γ. ∗∗∗p <
0.001. Data was pooled from three different experiments each with 2 animals per
genotype. Data is presented as mean ± SEM, statistical significance was
calculated using two-tailed Mann-Whitney test with Bonferroni correction.
Figure S3 | CD4+ cells were isolated from spleen of WT or miR-155−/− mice
and seeded in 96 well plates pre-coated with anti-CD3 or anti-CD3 and
anti-CD28. Supernatants were analyzed for the presence of (A) IL-2, (B) IFN-γ,
(C) TNF, (D) IL-4. Data was pooled from three different experiments each with 2
animals per genotype. Statistical significance was calculated using two-tailed
Mann-Whitney test with Bonferroni correction.
Figure S4 | CD45.1 mice received 3x106 miR-155−/− or WT OTII T cells were
infected 24 hours later with rVSV-OVA. Serum was collected 8 days after infection
and rVSV-OVA neurtralyzing antibodies were quantified by plaque assay as
explained in methods section. Results represented as mean ± SEM of two
different experiments with six animals per group.
Video S1 | 19-min capture of popliteal LNs excised from CD11c YFP C57BL/6
mice that received WT OTII T cells and were immunized in the footpad with
CFA/OVA. Red cells represent OTII T cells transferred (CMTPX) and green are DCs
(YFP) present in the LN.
Video S2 | 19-min capture of popliteal LNs excised from CD11c YFP C57BL/6
mice that received miR155−/− OTII T cells and were immunized in the footpad
with CFA/OVA. Red cells represent OTII T cells transferred (CMTPX) and green are
DCs (YFP) present in the LN.
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